Role of Novel Subcutaneous Daratumumab in Multiple Myeloma

June 1, 2020
Ola Landgen, MD, PhD

How the recent FDA approval of the subcutaneous formulation of daratumumab in multiple myeloma will affect patients and oncologists from practical and clinical standpoints.